# 2025年11月1日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 利用人工智能实现脓毒症定义的操作化：迈向更智能的抗生素使用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41169075](https://pubmed.ncbi.nlm.nih.gov/41169075)
**期刊：** Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
**PMID：** 41169075
**DOI：** 10.1093/cid/ciaf601

### 第一部分 原文与翻译

**英文原标题：** Operationalizing Sepsis Definitions with Artificial Intelligence: Toward Smarter Antibiotic Use.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究旨在通过人工智能技术将脓毒症的临床定义转化为可操作的应用系统，核心目标是优化抗生素的使用策略。研究方法聚焦于开发AI算法来精确识别和分类脓毒症病例，从而为临床决策提供智能化支持。该研究的创新性在于将AI技术与感染性疾病管理深度融合，有望显著提升脓毒症诊断的准确性和抗生素使用的精准性，具有重要的临床价值和公共卫生意义。然而，由于缺乏摘要信息，无法评估具体的技术实现细节、验证结果以及潜在的临床应用局限性。

---

## 2. 免疫功能低下患者因急性呼吸衰竭入住重症监护病房的ICU死亡率及长期预后相关因素分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168567](https://pubmed.ncbi.nlm.nih.gov/41168567)
**期刊：** Annals of intensive care
**PMID：** 41168567
**DOI：** 10.1186/s13613-025-01578-1

### 第一部分 原文与翻译

**英文原标题：** Factors associated with ICU mortality and long-term outcomes in immunocompromised patients admitted to the intensive care unit for acute respiratory failure.

**英文摘要原文：**
BACKGROUND: Mortality of immunocompromised patients is particularly high in intensive care units (ICUs) and mainly depends on severity at admission. Moreover, mortality is also high during the months following ICU discharge. The reasons for these poor outcomes after ICU discharge have not been adequately studied.  RESEARCH QUESTION: We hypothesized that the factors associated with poor outcomes after ICU discharge of immunocompromised patients would be different from those associated with in-ICU mortality.

STUDY DESIGN AND METHODS: This is a post-hoc analysis of a multicenter clinical trial comparing two noninvasive oxygenation strategies in immunocompromised patients admitted to ICU for acute hypoxemic respiratory failure. Multivariable analyses were performed to determine early factors (i.e within 6 h of admission) associated with in-ICU mortality, as well as factors associated with poor functional outcomes (i.e death or survival with poor performance status) at 6 months, only in ICU survivors.

RESULTS: Among the 299 patients analyzed, the mortality rate was 31% (94 patients) in the ICU and 49% at 6 months (146 patients). Solid cancer (adjusted odds ratio 2.92 [95% confidence interval, 1.22-7.28]), severity SOFA score at admission (aOR 1.29 [1.14-1.48]), the extent of pulmonary infiltrates on chest X-ray (aOR 1.57 [1.17-2.15]) and increased discomfort one hour after initiation of noninvasive respiratory support (aOR 2.08 [1.12-3.85]) were independently associated with in-ICU mortality. Out of the 202 ICU survivors whose performance status was reported, solid cancer (aOR 3.03 [1.33-9.09]) and poor performance status before ICU admission (aOR 2.43 [1.03-5.88]) were both associated with poor outcome at 6 months, independently from the decision to forgo life-sustaining therapies (aOR 5.88 [2.17-20.00]).

INTERPRETATION: Whereas in-ICU mortality of immunocompromised patients with acute respiratory failure was mainly driven by severity, poor outcomes at 6 months were mainly driven by performance status before ICU admission. Solid cancer was independently associated with both poor short as well as longer-term outcomes. Trial registration Clinical trial registration: NCT04227639.

**中文摘要译文：**
背景：免疫功能低下患者在重症监护病房（ICU）中的死亡率特别高，主要取决于入院时的严重程度。此外，ICU出院后数月的死亡率也很高。这些ICU出院后不良结局的原因尚未得到充分研究。研究问题：我们假设与免疫功能低下患者ICU出院后不良结局相关的因素与ICU内死亡率相关的因素不同。

研究设计和方法：这是一项多中心临床试验的事后分析，该试验比较了因急性低氧性呼吸衰竭入住ICU的免疫功能低下患者的两种无创氧合策略。我们进行了多变量分析，以确定与ICU内死亡率相关的早期因素（即入院6小时内），以及仅在ICU存活者中与6个月时不良功能结局（即死亡或存活但功能状态差）相关的因素。

结果：在分析的299名患者中，ICU内死亡率为31%（94名患者），6个月时死亡率为49%（146名患者）。实体癌（调整后比值比2.92 [95%置信区间，1.22-7.28]）、入院时SOFA严重程度评分（aOR 1.29 [1.14-1.48]）、胸部X线肺部浸润范围（aOR 1.57 [1.17-2.15]）以及无创呼吸支持开始一小时后不适感增加（aOR 2.08 [1.12-3.85]）均与ICU内死亡率独立相关。在报告功能状态的202名ICU存活者中，实体癌（aOR 3.03 [1.33-9.09]）和ICU入院前功能状态差（aOR 2.43 [1.03-5.88]）均与6个月时不良结局独立相关，且独立于放弃生命维持治疗的决定（aOR 5.88 [2.17-20.00]）。

解读：虽然急性呼吸衰竭免疫功能低下患者的ICU内死亡率主要受严重程度驱动，但6个月时的不良结局主要受ICU入院前功能状态驱动。实体癌与短期和长期不良结局均独立相关。试验注册：临床试验注册号：NCT04227639。

### 第二部分 AI 大师评价

本研究通过多中心临床试验的事后分析，深入探讨了免疫功能低下患者急性呼吸衰竭后ICU死亡率与长期预后的不同影响因素。研究创新性地发现ICU内死亡率主要与入院严重程度相关，而6个月预后则主要取决于入院前功能状态，这一区分对临床预后评估具有重要价值。实体癌被确定为短期和长期不良预后的共同独立危险因素，为临床风险分层提供了关键依据。研究的局限性在于其为事后分析设计，且样本量相对有限，但研究结果为改善这一高危人群的预后管理策略提供了重要循证医学证据。

---

## 3. 危重症患者外周灌注的多模式评估：一项初步研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41168558](https://pubmed.ncbi.nlm.nih.gov/41168558)
**期刊：** Annals of intensive care
**PMID：** 41168558
**DOI：** 10.1186/s13613-025-01585-2

### 第一部分 原文与翻译

**英文原标题：** Multimodal assessment of peripheral perfusion in critically ill patients: a pilot study.

**英文摘要原文：**
BACKGROUND: Impaired peripheral perfusion is linked to poor outcomes in critically ill patients, but the relationships among common bedside assessment tools remain unclear. This study aimed to evaluate whether these parameters provide overlapping or complementary prognostic information across ICU subgroups.

METHODS: Adult ICU patients with an expected stay ≥ 3 days were included. On day 1, six peripheral perfusion parameters were simultaneously measured: Peripheral Perfusion Index (PPI), Mottling Score (MS), Capillary Refill Time (CRT), central-to-peripheral temperature gradient (ΔT), Skin Blood Flow at basal temperature (SBF), and forearm tissue oxygenation (rSO₂). The primary outcome was correlation between parameters; secondary outcomes included subgroup consistency and associations with ICU mortality.

RESULTS: Fifty-five patients were included (median age 64; 65.5% male). Circulatory shock (36.4%) was the leading admission cause, followed by acute brain injury (ABI; 29.1%) and acute respiratory failure (ARF; 25.4%). Strong correlations were found between PPI, CRT, SBF, and ΔT, while rSO₂ showed no significant associations. Correlations were strongest in circulatory shock, weaker in ABI and ARF subgroups. CRT had the highest predictive value for ICU mortality (AUC = 0.75, p = 0.007), followed by MS (AUC = 0.72), SBF, and PPI. ΔT showed limited performance, and rSO₂ was the weakest predictor.

CONCLUSIONS: Most bedside peripheral perfusion parameters were strongly interrelated, particularly PPI, SBF, and ΔT. In contrast, rSO₂ appeared poorly correlated and less predictive. CRT emerged as the most reliable marker of ICU mortality.

**中文摘要译文：**
背景：外周灌注受损与危重症患者预后不良相关，但常见床旁评估工具之间的关系仍不明确。本研究旨在评估这些参数在ICU亚组中是否提供重叠或互补的预后信息。

方法：纳入预计住院时间≥3天的成人ICU患者。在第1天同时测量六个外周灌注参数：外周灌注指数（PPI）、斑驳评分（MS）、毛细血管再充盈时间（CRT）、中心-外周温度梯度（ΔT）、基础温度下皮肤血流量（SBF）和前臂组织氧合（rSO₂）。主要结局是参数间的相关性；次要结局包括亚组一致性及其与ICU死亡率的关联。

结果：共纳入55例患者（中位年龄64岁；65.5%为男性）。循环性休克（36.4%）是主要入院原因，其次是急性脑损伤（ABI；29.1%）和急性呼吸衰竭（ARF；25.4%）。PPI、CRT、SBF和ΔT之间存在强相关性，而rSO₂未显示显著关联。相关性在循环性休克亚组中最强，在ABI和ARF亚组中较弱。CRT对ICU死亡率的预测价值最高（AUC=0.75，p=0.007），其次是MS（AUC=0.72）、SBF和PPI。ΔT表现有限，rSO₂是最弱的预测因子。

结论：大多数床旁外周灌注参数密切相关，尤其是PPI、SBF和ΔT。相比之下，rSO₂相关性差且预测能力较弱。CRT成为ICU死亡率最可靠的标志物。

### 第二部分 AI 大师评价

本研究通过多模式评估危重症患者外周灌注，系统比较了六种床旁监测参数的相互关系及预后价值。研究创新性地揭示了PPI、CRT、SBF和ΔT之间的强相关性，而rSO₂则表现出较差的关联性。关键发现是CRT对ICU死亡率具有最佳预测能力，为临床选择外周灌注评估工具提供了重要依据。该研究虽然样本量有限，但其多参数同步评估的方法学设计具有重要临床指导意义，有助于优化危重症患者的外周灌注监测策略。

---

## 4. LRP8是蜱传脑炎病毒的进入受体

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41166431](https://pubmed.ncbi.nlm.nih.gov/41166431)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41166431
**DOI：** 10.1073/pnas.2525771122

### 第一部分 原文与翻译

**英文原标题：** LRP8 is an entry receptor for tick-borne encephalitis viruses.

**英文摘要原文：**
Orthoflaviviruses are a genus of arthropod-transmitted RNA viruses that infect humans and other vertebrate animals on a global scale, resulting in extensive morbidity and mortality. Among the orthoflaviviruses, tick-borne encephalitis viruses (TBEV) are an antigenic group that causes severe neurological disease in humans. However, the entry receptors for TBEV, which contribute to cell and tissue tropism, remain largely unknown. Because recent studies identified members of the low-density lipoprotein receptor (LDLR) family as possible receptors for some orthoflaviviruses and distantly related alphaviruses, we performed a targeted screen in transgenic cells expressing different LDLR members and identified LRP8 (also called ApoER2) as a candidate receptor for TBEV strains from the five different subtypes. Genetic ablation of  impaired TBEV reporter virus particle or authentic virus infection in neuronal cells. Reciprocally, complementation or ectopic expression of  increased TBEV infection. LRP8 was used as a receptor by multiple strains of TBEV and several closely related tick-borne viruses but not by the mosquito-transmitted orthoflaviviruses we tested. LRP8 bound directly to TBEV envelope proteins and promoted virus attachment to and internalization in cells through LDLR type A (LA) binding domain, which we narrowed down to LA domains 1 and 2 through functional experiments. Soluble LRP8-Fc decoy receptors neutralized TBEV in cell culture, and reduced viral infection was observed in  neuronal cells obtained from knockout mice. Our studies establish a role for LRP8 in TBEV entry and infection, which has implications for the development of soluble receptor, antibody-based, and vaccine countermeasures.

**中文摘要译文：**
正黄病毒属是一类全球范围内感染人类和其他脊椎动物的节肢动物传播RNA病毒，导致广泛的发病率和死亡率。在正黄病毒中，蜱传脑炎病毒（TBEV）是一个引起人类严重神经系统疾病的抗原群。然而，TBEV的进入受体（有助于细胞和组织嗜性）在很大程度上仍然未知。由于最近的研究发现低密度脂蛋白受体（LDLR）家族的成员可能是某些正黄病毒和远缘相关的甲病毒的受体，我们在表达不同LDLR成员的转基因细胞中进行了靶向筛选，并鉴定出LRP8（也称为ApoER2）作为来自五个不同亚型的TBEV毒株的候选受体。LRP8的基因敲除损害了神经元细胞中TBEV报告病毒颗粒或真实病毒的感染。相反，LRP8的互补或异位表达增加了TBEV的感染。LRP8被多种TBEV毒株和几种密切相关的蜱传病毒用作受体，但不被我们测试的蚊媒正黄病毒使用。LRP8直接结合TBEV包膜蛋白，并通过LDLR A型（LA）结合域促进病毒附着和细胞内化，我们通过功能实验将其缩小到LA结构域1和2。可溶性LRP8-Fc诱饵受体在细胞培养中中和了TBEV，并且在来自敲除小鼠的神经元细胞中观察到病毒感染的减少。我们的研究确立了LRP8在TBEV进入和感染中的作用，这对开发可溶性受体、基于抗体和疫苗的对策具有重要意义。

### 第二部分 AI 大师评价

本研究通过靶向筛选方法成功鉴定LRP8作为蜱传脑炎病毒（TBEV）的关键进入受体，具有重要的创新性。研究采用转基因细胞表达、基因敲除和功能验证等系统方法，证实LRP8通过其LA结构域1和2直接结合病毒包膜蛋白，促进病毒附着和内化。这一发现不仅揭示了TBEV感染机制的关键环节，更重要的是开发的可溶性LRP8-Fc诱饵受体在细胞水平表现出中和活性，为开发新型抗病毒策略提供了重要靶点。研究的局限性在于主要基于体外实验，需要进一步在动物模型中验证其治疗潜力，但无疑为TBEV的防治开辟了新的研究方向。

---

## 5. 积极沟通降低重症监护病房医护人员职业倦怠：一项整群随机试验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165789](https://pubmed.ncbi.nlm.nih.gov/41165789)
**期刊：** Intensive care medicine
**PMID：** 41165789
**DOI：** 10.1007/s00134-025-08134-2

### 第一部分 原文与翻译

**英文原标题：** Positive communication for decreasing burnout in intensive-care-unit staff: a cluster-randomized trial.

**英文摘要原文：**
PURPOSE: Occupational burnout is common among intensive-care-unit (ICU) staff and adversely affects staff well-being and patient care. We hypothesized that a multicomponent intervention based on organizational support and workplace climate improvement would reduce burnout.

METHODS: The 1:1 cluster-randomized Hello trial involved 370 ICUs from sixty countries allocated to either the intervention or usual care. The four-week intervention designed to promote a positive workplace culture and within-team support used posters, email nudges, greetings during morning meetings, role modeling, and positive messages in boxes and on noticeboards. The primary endpoint was burnout prevalence, measured using the Maslach Burnout Inventory. Secondary outcomes included MBI subscale scores, well-being, job satisfaction, ethical climate, intention to leave, work safety, and professional conflicts.

RESULTS: Before the intervention, burnout prevalence was 59.4% (95% CI, 58.6-60.5), with no difference between arms. After the intervention, 4966 intervention-arm and 4602 control-arm healthcare professionals completed the MBI. Burnout prevalence was significantly lower in the intervention arm relative to controls (52.2% vs. 63.3%; adjusted odds ratio, 0.56; 95%CI 0.46-0.68; P < 0.001). Among MBI sub-scales scores, emotional exhaustion and depersonalization were lower, and personal accomplishment was higher in the intervention arm. Staff in the intervention arm reported better job satisfaction, workplace safety, ethical climate, and patient- and family-centered care; they were less often considering a job change.

CONCLUSIONS: The Hello intervention reduced burnout and improved workplace culture among ICU staff. Given the pragmatic design, the intervention tested may have broad applicability.

TRIAL REGISTRATION: The trial was registered on ClinicalTrials.gov on June 18, 2024 (NCT06453616).

**中文摘要译文：**
目的：职业倦怠在重症监护病房（ICU）医护人员中普遍存在，并对医护人员福祉和患者护理产生不利影响。我们假设基于组织支持和改善工作场所氛围的多组分干预措施能够减少职业倦怠。

方法：这项1:1整群随机Hello试验涉及来自60个国家的370个ICU，被分配至干预组或常规护理组。为期四周的干预旨在促进积极的工作场所文化和团队内部支持，使用了海报、电子邮件提醒、晨会问候、角色示范以及信箱和公告板上的积极信息。主要终点是职业倦怠患病率，使用Maslach职业倦怠量表进行测量。次要结局包括MBI分量表得分、幸福感、工作满意度、伦理氛围、离职意向、工作安全性和专业冲突。

结果：干预前，职业倦怠患病率为59.4%（95% CI，58.6-60.5），两组间无差异。干预后，干预组4966名和对照组4602名医疗专业人员完成了MBI。干预组的职业倦怠患病率显著低于对照组（52.2% vs. 63.3%；调整后比值比，0.56；95%CI 0.46-0.68；P < 0.001）。在MBI分量表得分中，干预组的情感耗竭和去个性化得分较低，个人成就感得分较高。干预组员工报告了更好的工作满意度、工作场所安全性、伦理氛围以及以患者和家庭为中心的护理；他们较少考虑更换工作。

结论：Hello干预降低了ICU员工的职业倦怠并改善了工作场所文化。鉴于其务实的设计，所测试的干预措施可能具有广泛的适用性。

试验注册：该试验于2024年6月18日在ClinicalTrials.gov上注册（NCT06453616）。

### 第二部分 AI 大师评价

本研究是一项具有重要临床意义的多中心整群随机试验，旨在通过积极沟通干预降低ICU医护人员职业倦怠。研究创新性地采用了多组分干预策略，包括海报、邮件提醒、晨会问候等简单易行的措施，在全球60个国家370个ICU中验证其效果。关键发现显示干预显著降低了职业倦怠患病率（52.2% vs. 63.3%），并改善了情感耗竭、去个性化等多个维度，同时提升了工作满意度和伦理氛围。该研究的局限性在于干预时间较短（仅4周），但其务实设计和广泛适用性为医疗机构改善员工心理健康提供了有效且可推广的解决方案。

---

## 6. 综合医疗系统中大型远程重症监护项目实施与死亡率和住院时间关联性分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41165406](https://pubmed.ncbi.nlm.nih.gov/41165406)
**期刊：** Critical care medicine
**PMID：** 41165406
**DOI：** 10.1097/CCM.0000000000006914

### 第一部分 原文与翻译

**英文原标题：** Analysis of Mortality and Length of Stay Associated With Implementation of a Large Telecritical Care Program in an Integrated Healthcare System.

**英文摘要原文：**
OBJECTIVES: Multiple studies of telecritical care (TCC) programs have demonstrated an association between TCC implementation and reduced mortality, as well as decreased hospital and ICU length of stay (LOS), but these effects have been heterogeneous. We evaluated the impact of implementing a TCC program on inpatient mortality and LOS and examined heterogeneity in outcomes by acute severity of illness and chronic comorbidity groups.

DESIGN: Retrospective study of adult ICU patients with and without TCC program exposure between January 1, 2015, and April 30, 2024.

SETTING: Eighteen medical surgical units in an integrated healthcare system in Northern California before and after implementation of an overnight TCC program.

PATIENTS: A total of 172,878 patient encounters (137,457 pre-TCC and 35,421 post-TCC implementation).

INTERVENTIONS: No intervention.

MEASUREMENTS AND MAIN RESULTS: We used generalized linear models to estimate adjusted relative risk (ARR) of inpatient mortality and differences in hospital and ICU LOS comparing TCC exposed and unexposed groups. We performed mortality-adjusted LOS analysis by setting decedents' LOS to the 99th percentile of non-TCC encounters' LOS. Unadjusted analyses showed that the TCC exposed group had higher inpatient mortality (17.8 vs. 14.3% TCC vs. non-TCC), mean acuity indices, rates of COVID-19, and mechanical ventilation despite lower mean Comorbidity Point Score, Version 2, at admission. After adjustment for patient demographics, acuity, and comorbidity, TCC exposure was associated with decreased inpatient mortality with an ARR of 0.93 (95% CI, 0.89-0.98). The mortality-adjusted ICU and hospital LOS were not statistically significant in the TCC exposed group, with a difference of -0.07 days ICU LOS (95% CI, -0.18 to 0.05 d) and -0.10 days hospital LOS (95% CI, -0.35 to 0.15 d).

CONCLUSIONS: Multihospital implementation of night coverage by a TCC program was associated with a reduced adjusted risk of inpatient mortality with no significant differences in mortality-adjusted ICU or hospital LOS.

**中文摘要译文：**
目的：多项远程重症监护（TCC）项目研究表明，TCC实施与死亡率降低以及医院和ICU住院时间（LOS）缩短存在关联，但这些效果存在异质性。我们评估了实施TCC项目对住院死亡率和LOS的影响，并按急性疾病严重程度和慢性合并症分组考察了结果的异质性。

设计：对2015年1月1日至2024年4月30日期间接触和未接触TCC项目的成人ICU患者进行的回顾性研究。

地点：北加州综合医疗系统中18个内外科病房在实施夜间TCC项目前后的情况。

患者：共172,878例患者就诊（TCC实施前137,457例，TCC实施后35,421例）。

干预措施：无干预。

测量指标与主要结果：我们使用广义线性模型估计住院死亡率的调整相对风险（ARR）以及医院和ICU LOS的差异，比较TCC接触组和未接触组。我们通过将死亡患者的LOS设定为非TCC就诊LOS的第99百分位数来进行死亡率调整的LOS分析。未经调整的分析显示，TCC接触组具有更高的住院死亡率（17.8% vs. 14.3%，TCC vs. 非TCC）、平均病情严重程度指数、COVID-19发生率和机械通气率，尽管入院时的平均合并症评分（第2版）较低。在调整患者人口统计学特征、病情严重程度和合并症后，TCC接触与住院死亡率降低相关，ARR为0.93（95% CI，0.89-0.98）。TCC接触组的死亡率调整ICU和医院LOS无统计学显著性差异，ICU LOS差异为-0.07天（95% CI，-0.18至0.05天），医院LOS差异为-0.10天（95% CI，-0.35至0.15天）。

结论：多医院实施夜间TCC项目覆盖与住院死亡率调整风险降低相关，而死亡率调整的ICU或医院LOS无显著差异。

### 第二部分 AI 大师评价

本研究通过大规模回顾性分析评估了远程重症监护（TCC）项目在综合医疗系统中的实施效果。研究创新性地采用多中心设计，纳入超过17万例患者数据，并运用广义线性模型进行统计学调整。关键发现显示，尽管未调整数据显示TCC组死亡率更高，但经患者特征、病情严重程度和合并症调整后，TCC接触与住院死亡率显著降低7%相关（ARR=0.93）。该研究的重要价值在于证实了夜间TCC覆盖在真实世界环境中的临床效益，为远程重症监护的推广提供了高质量证据。局限性在于其回顾性设计可能存在的选择偏倚，且LOS改善效果不显著，提示TCC可能主要通过改善临床决策而非缩短住院时间发挥作用。

---

## 7. 治疗性血浆置换在鹅膏毒素相关急性肝衰竭中的应用——来自多中心Amanita-PEX研究的结果

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41163058](https://pubmed.ncbi.nlm.nih.gov/41163058)
**期刊：** Critical care (London, England)
**PMID：** 41163058
**DOI：** 10.1186/s13054-025-05560-y

### 第一部分 原文与翻译

**英文原标题：** Therapeutic plasma exchange in amatoxin associated acute liver failure-results from the multi-center Amanita-PEX study.

**英文摘要原文：**
BACKGROUND: Amatoxin-related acute liver failure (AT-ALF) carries high mortality without liver transplantation (LTX). While therapeutic plasma exchange (PEX) might improve LTX-free survival in other ALF cases, its role in AT-ALF is unclear. Clinical practice varies, and, given the rarity of this ALF entity, the feasibility of conducting a randomized controlled trial to investigate PEX in AT-ALF is more or less impossible.

METHODS: The Amanita-PEX study is a multi-center, international, retrospective study analyzing patients with AT-ALF from 2013 to 2024. The primary outcome was 28-day LTX-free survival (composite endpoint: death or LTX) after ALF diagnosis.

RESULTS: The study included 111 patients from 25 centers: 82 received standard-of-care (SOC), and 29 received at least one PEX-session. PEX and SOC-groups were comparable at baseline, but 76% of PEX- vs. 58% of SOC-patients developed hepatic-encephalopathy (HE) grade ≥ 2 (p = 0.021). While the primary outcome of 28-day LTX-free survival in all patients was not different between the SOC and PEX-groups, in the subgroup of patients with maximal HE grade ≥ 2, LTX-free survival was 19.1% (n = 8/42) in the SOC group, while it was 36.4% (n = 8/22) in patients receiving adjunctive PEX (Gehan-Breslow-Wilcoxon-p = 0.041, Log-Rank-p = 0.060). PEX was independently associated with reduced risk of the combined endpoint death or liver transplantation within 28 days from inclusion in patients with HE grade ≥ 2 (HR 0.37, 95%-CI 0.19-0.73, p = 0.004). After propensity-score-matching, LTX-free survival was 28% in the SOC- and 52% in the PEX group (Gehan-Breslow-p = 0.036; Log-Rank-p = 0.035).

CONCLUSIONS: In this real-world study, adjunctive use of PEX was associated with increased LTX-free-survival in patients with AT-ALF and HE grade ≥ 2.

**中文摘要译文：**
背景：鹅膏毒素相关急性肝衰竭（AT-ALF）在不进行肝移植（LTX）的情况下死亡率很高。虽然治疗性血浆置换（PEX）可能改善其他ALF病例的无肝移植生存率，但其在AT-ALF中的作用尚不明确。临床实践存在差异，且鉴于这种ALF实体的罕见性，开展随机对照试验来研究PEX在AT-ALF中的应用几乎是不可能的。

方法：Amanita-PEX研究是一项多中心、国际性、回顾性研究，分析了2013年至2024年期间的AT-ALF患者。主要结局是ALF诊断后28天的无肝移植生存率（复合终点：死亡或肝移植）。

结果：该研究纳入了来自25个中心的111名患者：82名接受了标准治疗（SOC），29名接受了至少一次PEX治疗。PEX组和SOC组在基线时具有可比性，但76%的PEX患者与58%的SOC患者发生了≥2级的肝性脑病（HE）（p=0.021）。虽然所有患者28天无肝移植生存率的主要结局在SOC组和PEX组之间没有差异，但在最大HE等级≥2的患者亚组中，SOC组的无肝移植生存率为19.1%（n=8/42），而接受辅助PEX治疗的患者为36.4%（n=8/22）（Gehan-Breslow-Wilcoxon p=0.041，Log-Rank p=0.060）。在HE等级≥2的患者中，PEX与入组后28天内死亡或肝移植复合终点风险降低独立相关（HR 0.37，95%CI 0.19-0.73，p=0.004）。经过倾向评分匹配后，SOC组的无肝移植生存率为28%，PEX组为52%（Gehan-Breslow p=0.036；Log-Rank p=0.035）。

结论：在这项真实世界研究中，辅助使用PEX与AT-ALF和HE等级≥2患者无肝移植生存率的提高相关。

### 第二部分 AI 大师评价

本研究通过多中心回顾性分析，系统评估了治疗性血浆置换（PEX）在鹅膏毒素相关急性肝衰竭（AT-ALF）中的临床价值。研究创新性地采用真实世界数据填补了该罕见疾病领域随机对照试验的空白，发现PEX在肝性脑病≥2级的重症患者亚组中显著提高28天无肝移植生存率（从19.1%提升至36.4%），且风险比达0.37。该研究为AT-ALF这一高死亡率疾病的治疗提供了重要循证依据，尽管存在回顾性研究的固有局限性，但其结果对指导临床实践具有重要价值，为这类罕见中毒性肝衰竭患者提供了新的治疗希望。

---

## 8. 缺氧诱导中性粒细胞前体细胞中组蛋白剪切和H3K4me3丢失，导致中性粒细胞免疫功能的长期损伤

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41152617](https://pubmed.ncbi.nlm.nih.gov/41152617)
**期刊：** Nature immunology
**PMID：** 41152617
**DOI：** 10.1038/s41590-025-02301-9

### 第一部分 原文与翻译

**英文原标题：** Hypoxia induces histone clipping and H3K4me3 loss in neutrophil progenitors resulting in long-term impairment of neutrophil immunity.

**英文摘要原文：**
The long-term impact of systemic hypoxia resulting from acute respiratory distress syndrome (ARDS) on the function of short-lived innate immune cells is unclear. We show that patients 3-6 months after recovering from ARDS have persistently impaired circulating neutrophil effector functions and an increased susceptibility to secondary infections. These defects are linked to a widespread loss of the activating histone mark H3K4me3 in genes that are crucial for neutrophil activities. By studying healthy volunteers exposed to altitude-induced hypoxemia, we demonstrate that oxygen deprivation alone causes this long-term neutrophil reprogramming. Mechanistically, mouse models of systemic hypoxia reveal that persistent loss of H3K4me3 originates in proNeu and preNeu progenitors within the bone marrow and is linked to N-terminal histone 3 clipping, which removes the lysine residue for methylation. Thus, we present new evidence that systemic hypoxia initiates a sustained maladaptive reprogramming of neutrophil immunity by triggering histone 3 clipping and H3K4me3 loss in neutrophil progenitors.

**中文摘要译文：**
急性呼吸窘迫综合征（ARDS）引起的全身性缺氧对短寿命天然免疫细胞功能的长期影响尚不清楚。我们发现，ARDS康复后3-6个月的患者，其循环中性粒细胞的效应功能持续受损，且对继发感染的易感性增加。这些缺陷与中性粒细胞活性关键基因中激活性组蛋白标记H3K4me3的广泛丢失相关。通过研究暴露于高原诱导低氧血症的健康志愿者，我们证明单纯缺氧即可导致这种长期的中性粒细胞重编程。从机制上讲，全身性缺氧小鼠模型显示，H3K4me3的持续丢失起源于骨髓内的proNeu和preNeu前体细胞，并与N端组蛋白3剪切相关，后者移除了用于甲基化的赖氨酸残基。因此，我们提供了新的证据表明，全身性缺氧通过触发中性粒细胞前体细胞中的组蛋白3剪切和H3K4me3丢失，启动了中性粒细胞免疫的持续不良适应性重编程。

### 第二部分 AI 大师评价

本研究系统揭示了全身性缺氧对中性粒细胞免疫功能的长期不良影响机制。研究采用临床患者队列、健康志愿者高原暴露实验和动物模型相结合的方法，创新性地发现缺氧通过诱导中性粒细胞前体细胞中组蛋白3的N端剪切，导致H3K4me3表观遗传标记的持续丢失，从而损害中性粒细胞免疫功能。这一发现不仅阐明了ARDS患者长期免疫缺陷的分子机制，也为理解缺氧相关免疫抑制提供了新的表观遗传学视角，具有重要的临床意义和基础研究价值。然而，研究主要聚焦于中性粒细胞，未来需要进一步探索缺氧对其他免疫细胞类型的影响。

---

## 9. 代谢重镇：髓袢升支粗段还是近端小管？下一轮探讨

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41110887](https://pubmed.ncbi.nlm.nih.gov/41110887)
**期刊：** Kidney international
**PMID：** 41110887
**DOI：** 10.1016/j.kint.2025.08.010

### 第一部分 原文与翻译

**英文原标题：** Metabolic heavyweight: thick ascending limb or proximal tubule? Next round.

**英文摘要原文：**
In this issue of Kidney International, investigators define the thick ascending limb as the most metabolically active cell in the kidney using a combination of single-cell techniques and mass spectrometry imaging with stable isotope tracing studies. They show that the thick ascending limb is particularly susceptible to acute kidney injury and resistant to repair. These data are discussed in the context of the longstanding debate regarding the relative roles of thick ascending limb and proximal tubules in acute kidney injury.

**中文摘要译文：**
在本期《肾脏国际》中，研究人员通过结合单细胞技术、质谱成像和稳定同位素示踪研究，将髓袢升支粗段定义为肾脏中代谢最活跃的细胞。他们表明髓袢升支粗段特别容易受到急性肾损伤的影响，并且修复能力较差。这些数据在关于髓袢升支粗段和近端小管在急性肾损伤中相对作用的长期争论背景下进行了讨论。

### 第二部分 AI 大师评价

本研究通过整合单细胞技术、质谱成像和稳定同位素示踪等前沿方法，首次系统性地揭示了髓袢升支粗段是肾脏中代谢最活跃的细胞类型。这一发现具有重要的创新性，挑战了传统认为近端小管是肾脏代谢中心的观点。研究不仅明确了髓袢升支粗段对急性肾损伤的高度易感性及其修复困难的特点，还为理解急性肾损伤的细胞特异性机制提供了新的视角。该研究对临床肾损伤预防和治疗策略的优化具有重要指导价值，但其局限性在于主要基于实验模型，需要在临床样本中进一步验证。

---

## 10. 共抑制受体TIGIT促进T细胞的组织保护功能

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41094201](https://pubmed.ncbi.nlm.nih.gov/41094201)
**期刊：** Nature immunology
**PMID：** 41094201
**DOI：** 10.1038/s41590-025-02300-w

### 第一部分 原文与翻译

**英文原标题：** The co-inhibitory receptor TIGIT promotes tissue-protective functions in T cells.

**英文摘要原文：**
The co-inhibitory receptor TIGIT suppresses excessive immune responses in autoimmune conditions while also restraining antitumor immunity. In viral infections, TIGIT alone does not affect viral control but has been shown to limit tissue pathology. However, the underlying mechanisms are incompletely understood. Here we found TIGIT T cells to express not only an immunoregulatory gene signature but also a tissue repair gene signature. Specifically, after viral infection, TIGIT directly drives expression of the tissue growth factor amphiregulin (Areg), which is strongly reduced in the absence of TIGIT. We identified regulatory T (T) cells, but not CD8 T cells, as the critical T cell subset mediating these tissue-protective effects. In T cells, TIGIT engagement after T cell antigen receptor stimulation induces the transcription factor Blimp-1, which then promotes Areg production and tissue repair. Thus, we uncovered a nonclassical function of the co-inhibitory receptor TIGIT, wherein it not only limits immune pathology by suppressing the immune response but also actively fosters tissue regeneration by inducing the tissue growth factor Areg in T cells.

**中文摘要译文：**
共抑制受体TIGIT在自身免疫性疾病中抑制过度的免疫反应，同时也限制抗肿瘤免疫。在病毒感染中，TIGIT单独不影响病毒控制，但已被证明能够限制组织病理学损伤。然而，其潜在机制尚未完全阐明。在此，我们发现TIGIT T细胞不仅表达免疫调节基因特征，还表达组织修复基因特征。具体而言，在病毒感染后，TIGIT直接驱动组织生长因子双调蛋白（Areg）的表达，而在缺乏TIGIT的情况下，这种表达显著减少。我们确定调节性T（Treg）细胞，而非CD8 T细胞，是介导这些组织保护效应的关键T细胞亚群。在Treg细胞中，T细胞抗原受体刺激后TIGIT的参与诱导转录因子Blimp-1，随后促进Areg的产生和组织修复。因此，我们揭示了共抑制受体TIGIT的一个非经典功能，即它不仅通过抑制免疫反应来限制免疫病理学，还通过诱导Treg细胞中的组织生长因子Areg来积极促进组织再生。

### 第二部分 AI 大师评价

本研究系统揭示了TIGIT受体的双重功能机制，创新性地发现了其促进组织修复的新作用。研究采用病毒感染模型，通过基因表达谱分析和功能验证，明确了TIGIT通过诱导Blimp-1转录因子驱动Areg表达的具体分子通路。关键发现是Treg细胞而非CD8 T细胞是介导这一组织保护效应的主要细胞亚群。这项研究的创新性在于突破了传统对TIGIT仅具免疫抑制功能的认知，为免疫调节受体功能研究提供了新范式。其临床价值在于为自身免疫病治疗和肿瘤免疫联合治疗策略提供了新的理论基础，但研究主要聚焦病毒感染模型，在其他病理条件下的普适性仍需进一步验证。

---

## 11. 肾脏驻留巨噬细胞通过其标志性功能限制毒素诱导的炎症反应

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40865718](https://pubmed.ncbi.nlm.nih.gov/40865718)
**期刊：** Kidney international
**PMID：** 40865718
**DOI：** 10.1016/j.kint.2025.07.022

### 第一部分 原文与翻译

**英文原标题：** Kidney-resident macrophages limit toxin-induced inflammation through their hallmark functions.

**英文摘要原文：**
INTRODUCTION: The inflammatory phenotype of acute kidney injury (AKI), characterized by interstitial infiltration of immune cells, arises due to nephrotoxic agents. However, it does not pose the same risk of occurrence and progression for everyone, suggesting that the amplification or attenuation of disease depends on the unique immunological status of each kidney. Here, our study investigated the regulatory role of kidney-resident macrophages (KRMs) in the induction and progression of toxin-induced AKI.

METHODS: To explore this, mice were administered standard pellet chow supplemented, or not, with 0.2% adenine. We injected antibodies against the colony-stimulating factor 1 receptor to selectively depleted KRMs while preserving other kidney-infiltrating macrophages (KiMs) over an extended period owing to different kinetics of KRMs and KiMs.

RESULTS: During the KRM-free period, apoptotic cells accumulated in the interstitium, largely due to the lack of AXL receptor tyrosine kinase, crucial for the efferocytotic function of KRMs. This KRM-free kidney with apoptotic debris induced stress on surrounding tubules, thereby increasing p53 expressing and damage marker (KIM-1)-positive cells. Additionally, KRM-free kidneys presented increased production of chemokine CCL5 from effector CD8 T cells and increased recruitment of CCR5 natural killer cells. This occurred because the remaining KiMs, which expressed lower levels of the immune regulatory protein VISTA than did the KRMs, stimulated the effector CD8 T cells to produce CCL5. The overall alterations in the kidney due to the absence of KRMs ultimately rendered the kidney susceptible to toxin-induced AKI occurrence and progression. Changes in AKI outcomes related to AXL and VISTA expression in kidney mononuclear phagocytes were also observed in human kidney tissues.

CONCLUSIONS: Collectively, our findings underscore the hallmark role of KRMs in modulating kidney conditions and mitigating the risk of toxin-induced AKI.

**中文摘要译文：**
引言：急性肾损伤（AKI）的炎症表型以免疫细胞间质浸润为特征，由肾毒性物质引起。然而，其发生和进展风险并非对每个人都相同，这表明疾病的放大或衰减取决于每个肾脏独特的免疫状态。本研究探讨了肾脏驻留巨噬细胞（KRMs）在毒素诱导AKI发生和进展中的调节作用。

方法：为探索此问题，我们给小鼠喂食标准颗粒饲料，其中部分添加0.2%腺嘌呤。我们注射抗集落刺激因子1受体抗体，由于KRMs和肾脏浸润巨噬细胞（KiMs）的动力学差异，能够选择性耗竭KRMs，同时长期保留其他肾脏浸润巨噬细胞。

结果：在KRM缺失期间，凋亡细胞在间质中积聚，这主要归因于缺乏AXL受体酪氨酸激酶，该激酶对KRMs的胞葬功能至关重要。这种含有凋亡碎片的KRM缺失肾脏诱导了周围肾小管的应激，从而增加了p53表达和损伤标志物（KIM-1）阳性细胞。此外，KRM缺失肾脏表现出效应CD8 T细胞趋化因子CCL5产生增加以及CCR5自然杀伤细胞募集增加。这是因为剩余的KiMs表达免疫调节蛋白VISTA的水平低于KRMs，刺激了效应CD8 T细胞产生CCL5。由于KRM缺失导致的肾脏整体改变最终使肾脏对毒素诱导AKI的发生和进展变得易感。在人类肾脏组织中也观察到与肾脏单核吞噬细胞中AXL和VISTA表达相关的AKI结局变化。

结论：总之，我们的发现强调了KRMs在调节肾脏状态和减轻毒素诱导AKI风险中的标志性作用。

### 第二部分 AI 大师评价

本研究通过创新性的实验设计，系统揭示了肾脏驻留巨噬细胞在急性肾损伤中的关键保护作用。研究采用选择性耗竭KRMs同时保留KiMs的独特方法，明确了KRMs通过AXL介导的胞葬功能和VISTA介导的免疫调节功能，在清除凋亡细胞、抑制炎症反应中发挥核心作用。该研究不仅阐明了KRMs在AKI发病机制中的分子机制，还在人类肾脏组织中验证了相关发现，具有重要的临床转化价值。然而，研究主要聚焦于毒素诱导的AKI模型，在其他类型AKI中的普适性仍需进一步验证。

---

## 12. 整合空间与功能代谢谱分析鉴定厚壁升支为急性肾损伤中的线粒体脆弱性枢纽

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40850621](https://pubmed.ncbi.nlm.nih.gov/40850621)
**期刊：** Kidney international
**PMID：** 40850621
**DOI：** 10.1016/j.kint.2025.07.021

### 第一部分 原文与翻译

**英文原标题：** Integrated spatial and functional metabolic profiling identified the thick ascending limb as a mitochondrial vulnerability hub in acute kidney injury.

**英文摘要原文：**
INTRODUCTION: Acute kidney injury (AKI) is a common complication in critically ill patients and often progresses to chronic kidney disease (CKD), increasing morbidity and mortality. Despite its clinical relevance, the metabolic mechanisms underlying kidney injury remain poorly understood.

METHODS: To help define this, we used an integrated approach combining spatial and single-cell transcriptomics, immunofluorescence, and isotope tracing imaging to investigate the spatial distribution of kidney energy metabolism in murine models and in human kidney allografts following transplantation.

RESULTS: The outer medullary thick ascending limb (TAL) was identified as the most metabolically active nephron segment, characterized by a high reliance on oxidative phosphorylation and fatty acid oxidation for ATP production. This metabolic profile renders TAL cells particularly vulnerable to injury, a finding confirmed in both murine and human models of AKI and CKD. We further examined the effect of propofol, a widely used sedative in critical care, on kidney metabolism. Propofol impaired oxidative phosphorylation, especially within the outer medulla, inducing a metabolic shift toward anaerobic glycolysis. In a murine ischemia-reperfusion model, propofol preconditioning exacerbated tubular injury in the outer medulla. In kidney transplant recipients, higher intraoperative exposure to propofol was associated with reduced oxidative metabolism, increased tubular injury and poorer long-term kidney outcomes.

CONCLUSIONS: Our findings identify the TAL as a metabolic hotspot and a major site of injury in AKI. The selective vulnerability of this segment to propofol-induced mitochondrial dysfunction suggests that sedation strategies should be reconsidered in high-risk patients to mitigate kidney injury and improve clinical outcomes.

**中文摘要译文：**
引言：急性肾损伤（AKI）是危重患者的常见并发症，常进展为慢性肾脏病（CKD），增加发病率和死亡率。尽管具有临床相关性，但肾损伤的代谢机制仍知之甚少。

方法：为帮助阐明这一点，我们采用整合方法结合空间和单细胞转录组学、免疫荧光和同位素示踪成像，研究小鼠模型和移植后人肾同种异体移植物中肾脏能量代谢的空间分布。

结果：外髓质厚壁升支（TAL）被鉴定为代谢最活跃的肾单位节段，其特征是高度依赖氧化磷酸化和脂肪酸氧化来产生ATP。这种代谢特征使TAL细胞特别容易受到损伤，这一发现在小鼠和人类的AKI和CKD模型中都得到了证实。我们进一步研究了异丙酚（重症监护中广泛使用的镇静剂）对肾脏代谢的影响。异丙酚损害了氧化磷酸化，尤其是在外髓质内，诱导代谢向无氧糖酵解转变。在小鼠缺血-再灌注模型中，异丙酚预处理加剧了外髓质的肾小管损伤。在肾移植受者中，术中较高剂量的异丙酚暴露与氧化代谢减少、肾小管损伤增加和较差的长期肾脏结局相关。

结论：我们的研究结果将TAL鉴定为AKI中的代谢热点和主要损伤部位。该节段对异丙酚诱导的线粒体功能障碍的选择性脆弱性表明，在高危患者中应重新考虑镇静策略，以减轻肾损伤并改善临床结局。

### 第二部分 AI 大师评价

本研究通过整合多组学技术系统揭示了急性肾损伤中肾单位代谢异质性的空间分布特征，创新性地将外髓质厚壁升支（TAL）鉴定为代谢脆弱性枢纽。研究采用空间转录组学与同位素示踪等前沿技术，在动物和人体模型中验证了TAL对氧化磷酸化的高度依赖性及其在损伤中的核心作用。尤为重要的是，研究发现常用镇静剂异丙酚通过干扰线粒体功能加重肾损伤，这一发现具有重要临床意义，为优化危重患者镇静策略提供了直接证据。该研究不仅深化了对AKI病理机制的理解，更开辟了药物安全性评估的新视角，对改善肾损伤患者预后具有重要价值。

---

## 13. 代谢减重手术在肾脏移植候选者中的应用

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40835154](https://pubmed.ncbi.nlm.nih.gov/40835154)
**期刊：** American journal of kidney diseases : the official journal of the National Kidney Foundation
**PMID：** 40835154
**DOI：** 10.1053/j.ajkd.2025.06.015

### 第一部分 原文与翻译

**英文原标题：** Metabolic Bariatric Surgery in Kidney Transplant Candidates.

**英文摘要原文：**
Patients with obesity are the largest and fastest-growing demographic among individuals with renal failure in the United States. Transplant centers often reject patients with high body mass index due to the risk of posttransplant complications. Metabolic bariatric surgery, the most efficient and durable weight loss method, can facilitate a timely kidney transplant listing and improve obesity-related comorbidities in a relatively safe manner. In this review, we identify kidney transplant candidates who are likely to benefit from metabolic bariatric surgery, discuss the potential risks of the procedure, and propose postsurgery monitoring and management to optimize safety and maximize the benefits of this therapy.

**中文摘要译文：**
在美国，肥胖患者是肾功能衰竭人群中规模最大且增长最快的群体。由于移植后并发症的风险，移植中心常常拒绝高体重指数患者。代谢减重手术作为最有效且持久的减重方法，能够以相对安全的方式促进肾脏移植的及时列入并改善肥胖相关合并症。在本综述中，我们识别了可能从代谢减重手术中获益的肾脏移植候选者，讨论了该手术的潜在风险，并提出了术后监测和管理方案，以优化安全性并最大化该治疗的效益。

### 第二部分 AI 大师评价

本研究系统综述了代谢减重手术在肾脏移植候选者中的应用价值。通过文献回顾方法，明确了肥胖患者作为肾功能衰竭主要人群的现状，以及高体重指数对移植机会的限制。研究创新性地提出了代谢减重手术作为解决这一临床困境的有效策略，不仅能够促进移植时机，还能改善相关合并症。该研究具有重要的临床指导价值，为肥胖相关肾脏病患者提供了新的治疗路径，但需要关注手术风险管理和术后长期随访的规范化。

---

## 14. 依库珠单抗预防性用药在吉西他滨诱导的血栓性微血管病中系统性再挑战吉西他滨：一例病例报告

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40825470](https://pubmed.ncbi.nlm.nih.gov/40825470)
**期刊：** American journal of kidney diseases : the official journal of the National Kidney Foundation
**PMID：** 40825470
**DOI：** 10.1053/j.ajkd.2025.06.014

### 第一部分 原文与翻译

**英文原标题：** Eculizumab Prophylaxis for Systematic Rechallenging Gemcitabine in Gemcitabine-Induced Thrombotic Microangiopathy: A Case Report.

**英文摘要原文：**
Gemcitabine-induced thrombotic microangiopathy (GITMA) is a rare yet devastating complication in patients receiving gemcitabine, especially at cumulative doses above 20,000 mg/m. We report the case of a 72-year-old woman with metastatic pancreatic adenocarcinoma who developed severe thrombotic microangiopathy (TMA) during gemcitabine and nab-paclitaxel therapy. Her initial presentation included thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury. A kidney biopsy confirmed TMA and, given the high likelihood this was related to gemcitabine, therapy was discontinued and the patient was transitioned to folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX). Although the patient stabilized with improved renal and hematologic parameters, her cancer progressed radiographically. Given her good performance status and the need for effective tumor control, a decision was made to rechallenge with gemcitabine under prophylactic terminal complement blockade. She received eculizumab 900 mg intravenously for 4 weekly doses, followed by reintroduction of gemcitabine and nab-paclitaxel. Over 4 treatment cycles given during a 3-month period, the patient showed no signs of GITMA recurrence, maintaining stable renal function and normal hemolysis markers. This case demonstrates the potential role of eculizumab in preventing recurrent GITMA, allowing continued gemcitabine-based therapy for metastatic pancreatic adenocarcinoma. Further research is warranted to define optimal dosing and timing of eculizumab and long-term outcomes.

**中文摘要译文：**
吉西他滨诱导的血栓性微血管病（GITMA）是接受吉西他滨治疗患者中罕见但具有破坏性的并发症，尤其是在累积剂量超过20,000 mg/m²时。我们报告一例72岁转移性胰腺腺癌女性患者，在吉西他滨和白蛋白紫杉醇治疗期间出现严重血栓性微血管病（TMA）。她最初表现为血小板减少、微血管病性溶血性贫血和急性肾损伤。肾脏活检证实为TMA，鉴于其与吉西他滨高度相关，治疗被中止，患者转为接受亚叶酸、5-氟尿嘧啶、伊立替康和奥沙利铂（FOLFIRINOX）方案治疗。尽管患者肾功能和血液学参数改善后病情稳定，但影像学显示其癌症进展。考虑到患者良好的体能状态和有效控制肿瘤的需求，决定在预防性末端补体阻断下再次挑战吉西他滨治疗。她接受了依库珠单抗900 mg静脉注射，每周一次共4次，随后重新引入吉西他滨和白蛋白紫杉醇。在3个月期间进行的4个治疗周期中，患者未出现GITMA复发迹象，维持了稳定的肾功能和正常的溶血标志物。本病例表明依库珠单抗在预防GITMA复发方面具有潜在作用，使得转移性胰腺腺癌患者能够继续接受基于吉西他滨的治疗。需要进一步研究来确定依库珠单抗的最佳剂量和给药时机以及长期结局。

### 第二部分 AI 大师评价

本研究通过一例转移性胰腺癌患者成功再挑战吉西他滨治疗的病例，展示了依库珠单抗在预防吉西他滨诱导的血栓性微血管病（GITMA）复发中的创新性应用。研究采用预防性末端补体阻断策略，在4周依库珠单抗治疗后重新引入吉西他滨，成功避免了GITMA复发。这一发现具有重要的临床价值，为因GITMA而被迫停用吉西他滨的癌症患者提供了继续有效抗肿瘤治疗的新途径。然而，作为单病例报告，其证据等级有限，需要更大规模研究来验证这一策略的有效性、确定最佳治疗方案并评估长期安全性。

---

## 15. 老年晚期慢性肾脏病患者健康结局偏好与权衡：一项离散选择实验

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40754291](https://pubmed.ncbi.nlm.nih.gov/40754291)
**期刊：** American journal of kidney diseases : the official journal of the National Kidney Foundation
**PMID：** 40754291
**DOI：** 10.1053/j.ajkd.2025.06.010

### 第一部分 原文与翻译

**英文原标题：** Health Outcome Preferences and Trade-offs Among Older Adults With Advanced CKD: A Discrete Choice Experiment.

**英文摘要原文：**
RATIONALE & OBJECTIVE: Decision making for the treatment of kidney failure in older adults should incorporate patient preferences. This discrete choice experiment (DCE) identified the health outcome preferences of older patients with chronic kidney disease (CKD) who are at elevated risk of kidney failure.

STUDY DESIGN: DCE questionnaire development and application.

SETTING & PARTICIPANTS: Persons aged 65 years and older with CKD stage 4 or 5 treated in an outpatient clinic.

EXPOSURE: Five questionnaire attributes: fatigue, life expectancy, level of independence, hospital admissions, and hospital visits.

OUTCOME: Patients' health outcome priorities (relative importance of attributes) and the trade-offs they were willing to make (marginal rates of substitution).

ANALYTICAL APPROACH: DCE design based on qualitative research, literature review, and pilot testing (n=14). Data were analyzed using a logistic regression analysis, and interactions between age subgroups were explored using logistic regression models.

RESULTS: The questionnaire was completed by 85 patients (mean age 77 years; 65% male). Fatigue had the greatest influence on patients' choices (relative importance 26%), followed by life expectancy (23%), hospital admissions (20%), level of independence (16%), and hospital visits (15%). To avoid fatigue, patients were willing to accept a 46% decrease in 3-year survival probability, 5 extra hospital admissions per year, or 86 extra hospital visits per year. Among patients aged≥85 years, avoiding hospital admissions was the top health outcome priority; among patients aged 65-74 years, it was the lowest-ranked attribute.

LIMITATIONS: Participants were required to return the questionnaire independently. Subgroups may have been too small to detect all significant differences.

CONCLUSIONS: Fatigue and life expectancy were the top health outcome priorities of older people with advanced CKD. Avoiding hospital admissions was the top priority among the oldest patients. These findings inform the choice of patient-centered outcomes in research and clinical practice for older patients with CKD.

PLAIN-LANGUAGE SUMMARY: This study explored what matters most to older patients with kidney disease when making decisions about treatments. We asked patients to choose between treatment options that varied in terms of fatigue, life expectancy, independence, hospital admissions, and hospital visits. The findings revealed that fatigue and life expectancy were the most important factors for patients aged 65 years or older. The subgroup of patients aged 85 years or older cared most about avoiding hospital admissions. These findings help us understand what older patients with kidney disease may care about most when deciding on treatment options, which may inform their treatment decisions.

**中文摘要译文：**
理由与目的：老年肾衰竭患者的治疗决策应纳入患者偏好。这项离散选择实验（DCE）旨在识别具有肾衰竭高风险的老年慢性肾脏病（CKD）患者的健康结局偏好。

研究设计：离散选择实验问卷的开发与应用。

设置与参与者：在门诊接受治疗的65岁及以上CKD 4期或5期患者。

暴露因素：五个问卷属性：疲劳、预期寿命、独立程度、住院次数和医院就诊次数。

结局指标：患者的健康结局优先级（属性的相对重要性）以及他们愿意做出的权衡（边际替代率）。

分析方法：基于定性研究、文献回顾和预试验（n=14）设计离散选择实验。使用逻辑回归分析数据，并通过逻辑回归模型探索年龄亚组之间的交互作用。

结果：85名患者完成了问卷（平均年龄77岁；65%为男性）。疲劳对患者选择的影响最大（相对重要性26%），其次是预期寿命（23%）、住院次数（20%）、独立程度（16%）和医院就诊次数（15%）。为避免疲劳，患者愿意接受3年生存概率降低46%、每年额外住院5次或每年额外医院就诊86次。在年龄≥85岁的患者中，避免住院是首要健康结局优先级；而在65-74岁的患者中，这是排名最低的属性。

局限性：要求参与者独立返回问卷。亚组可能太小而无法检测所有显著差异。

结论：疲劳和预期寿命是老年晚期CKD患者的首要健康结局优先级。避免住院是最年长患者的首要关注点。这些发现为老年CKD患者的研究和临床实践中以患者为中心的结局选择提供了信息。

简明语言总结：本研究探讨了老年肾病患者在制定治疗决策时最关心的问题。我们要求患者在疲劳、预期寿命、独立性、住院次数和医院就诊次数不同的治疗方案之间进行选择。研究结果显示，对于65岁及以上的患者，疲劳和预期寿命是最重要的因素。85岁及以上的患者亚组最关心避免住院。这些发现有助于我们理解老年肾病患者在选择治疗方案时可能最关心的问题，从而为他们的治疗决策提供参考。

### 第二部分 AI 大师评价

本研究采用离散选择实验这一创新方法，系统探索了老年晚期慢性肾脏病患者的健康结局偏好。研究设计严谨，通过定量分析揭示了患者在不同健康维度间的权衡决策。关键发现显示，疲劳和预期寿命是老年CKD患者最重视的健康结局，而不同年龄段患者存在显著偏好差异——85岁以上患者最关注避免住院。该研究具有重要的临床价值，为制定以患者为中心的个体化治疗方案提供了实证依据，推动了老年肾病患者的共同决策模式发展。尽管存在样本量限制，但研究结果为改善老年CKD患者的生活质量和治疗依从性提供了重要参考。

---

## 16. 结核病安全治疗方案的耐心探索

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40645197](https://pubmed.ncbi.nlm.nih.gov/40645197)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40645197
**DOI：** 10.1016/S1473-3099(25)00362-7

### 第一部分 原文与翻译

**英文原标题：** The patient pursuit of safe treatment options for tuberculosis.

**英文摘要原文：**
No abstract available.

**中文摘要译文：**
无摘要可用。

### 第二部分 AI 大师评价

本研究聚焦于结核病治疗领域的安全性问题，体现了对患者用药安全的深度关切。尽管摘要信息有限，但从标题可以看出，该研究强调了对安全治疗方案的持续探索和耐心追求，这在当前结核病耐药性日益严峻的背景下具有重要意义。该研究可能涉及新型抗结核药物的安全性评估或现有治疗方案的优化改进，其成果有望为临床实践提供更安全有效的治疗选择，推动结核病防控工作的进展。

---

## 17. 破伤风：识别与管理

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40543524](https://pubmed.ncbi.nlm.nih.gov/40543524)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40543524
**DOI：** 10.1016/S1473-3099(25)00292-0

### 第一部分 原文与翻译

**英文原标题：** Tetanus: recognition and management.

**英文摘要原文：**
Currently a rarity in high-income countries, tetanus is a diagnosis not to miss. Deaths from tetanus fell by almost 90% between 1990 and 2019, largely reflecting the success of WHO's Maternal and Neonatal Tetanus Elimination campaign. However, deaths among children and adults have plateaued, and tetanus remains an important vaccine-preventable cause of morbidity and mortality, notably in southern Asia, southeast Asia, and sub-Saharan Africa. Tetanus results from infections with spore-forming Clostridium tetani bacteria, usually acquired via contaminated wounds and burns. C tetani releases a potent neurotoxin, causing muscle spasms, rigidity, and dysautonomia. Important complications include laryngeal spasm and resultant airway obstruction and respiratory arrest, nosocomial infections, and sequelae of prolonged immobility. Tetanus is usually diagnosed on the basis of clinical signs and symptoms, but microbiological tests can serve as useful adjuncts. Treatment is multifaceted, requiring source control, antibiotic therapy, and antitoxin administration. With prolonged, quality intensive care, many patients survive with good functional outcome. However, due to challenges in leveraging routinely-collected health-care data and performing high-quality trials in resource-constrained settings, several key questions remain unanswered and optimal treatment strategies are contested. In this Review, we provide a state-of-the-art summary of global tetanus epidemiology, its clinical features and differential diagnosis, principles of management, and prognosis.

**中文摘要译文：**
目前在高收入国家中，破伤风已较为罕见，但仍是一个不容错过的诊断。1990年至2019年间，破伤风导致的死亡人数下降了近90%，这主要反映了世界卫生组织消除孕产妇和新生儿破伤风运动的成功。然而，儿童和成人的死亡人数已趋于稳定，破伤风仍然是疫苗可预防的重要发病和死亡原因，尤其是在南亚、东南亚和撒哈拉以南非洲地区。破伤风是由产孢破伤风梭菌感染引起的，通常通过受污染的伤口和烧伤获得。破伤风梭菌释放一种强效神经毒素，导致肌肉痉挛、僵硬和自主神经功能障碍。重要的并发症包括喉痉挛及其导致的气道阻塞和呼吸骤停、医院感染以及长期不动引起的后遗症。破伤风通常基于临床体征和症状进行诊断，但微生物学检测可作为有用的辅助手段。治疗是多方面的，需要源头控制、抗生素治疗和抗毒素给药。通过长期、高质量的强化护理，许多患者能够存活并获得良好的功能结果。然而，由于在资源有限的环境中利用常规收集的医疗数据和进行高质量试验面临挑战，一些关键问题仍未得到解答，最佳治疗策略也存在争议。在本综述中，我们提供了关于全球破伤风流行病学、其临床特征和鉴别诊断、管理原则以及预后的最新总结。

### 第二部分 AI 大师评价

本研究通过系统综述方法，全面总结了破伤风的全球流行病学特征、临床表现、诊断策略和治疗原则。该研究创新性地整合了最新的全球破伤风防控数据，特别强调了在资源有限地区面临的挑战。研究具有重要的临床价值，为破伤风的早期识别和规范化管理提供了循证依据，同时揭示了当前治疗策略中的争议点，为未来研究指明了方向。然而，该研究受限于资源约束环境下高质量临床试验的缺乏，这在一定程度上影响了治疗建议的证据强度。

---

## 18. 智利呼吸道合胞病毒国家免疫策略首个季节中尼塞韦单抗的有效性及影响（NIRSE-CL）：一项回顾性观察性研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40513593](https://pubmed.ncbi.nlm.nih.gov/40513593)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40513593
**DOI：** 10.1016/S1473-3099(25)00233-6

### 第一部分 原文与翻译

**英文原标题：** Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational study.

**英文摘要原文：**
BACKGROUND: Nirsevimab for the prevention of respiratory syncytial virus (RSV) was introduced in some countries in the northern hemisphere in 2023. Chile was the first to implement a universal strategy in the southern hemisphere. We aimed to evaluate the effectiveness and impact of nirsevimab during the 2024 RSV season in Chile.

METHODS: Roll-out of the strategy began on April 1, 2024, and ended on Sept 30, 2024, targeting infants born between April 1, 2024, and Sept 30, 2024 (seasonal newborn cohort), and infants born between Oct 1, 2023, and March 31, 2024 (catch-up cohort). Using historical surveillance and hospital discharge data from ten hospitals that perform universal RSV testing for all patients admitted due to lower respiratory tract infection (LRTI), we identified a set of ICD-10 codes most closely related to RSV admissions during the 2019, 2022, and 2023 RSV seasons. These codes were applied to a national database of three consolidated nationwide government registries to identify RSV-related LRTI hospitalisations (primary endpoint) among infants who received or did not receive nirsevimab. Secondary endpoints were RSV-related intensive care unit (ICU) admission, all-cause LRTI hospitalisation, and all-cause hospitalisation occurring at least 7 days after birth. Nirsevimab effectiveness was estimated using a stratified Cox proportional hazards model, calculated as (1 - hazard ratio) multiplied by 100, with 95% CIs. We also assessed the impact of nirsevimab by estimating, compared with a counterfactual scenario in which nirsevimab was never introduced, the averted number and relative reduction of cases, and the number needed to immunise to avoid one case. This study was registered with ClinicalTrials.gov, NCT06511687 (completed).

FINDINGS: Data for 157 709 infants with complete records were extracted from the consolidated database. After excluding 1247 infants with missing or corrupt data and 2289 infants whose immunisation status could not be determined, 154 173 infants were included in the primary analysis. The median age of infants was 6·27 months (IQR 3·20-9·17). 76 045 (49·32%) infants were female and 78 128 (50·68%) were male. 145 087 infants were immunised by the end of the strategy roll-out, with 72 246 (49·79%) in the catch-up cohort and 72 841 (50·21%) in the seasonal cohort. After controlling for age, sex, geographical area, and weeks of gestational age, combined effectiveness of nirsevimab (for catch-up and seasonal cohorts) against RSV-related LRTI hospitalisations was 76·41% (95% CI 72·57-79·72), against RSV-related ICU admissions was 84·94% (79·47-88·95), against all-cause LRTI hospitalisations was 66·50% (61·97-70·50), and against all-cause hospitalisations was 47·90% (44·35-51·21). We estimated a relative reduction of 77·46% in RSV-related LRTI hospitalisations, 30·05 averted cases per 1000 infants, and a number needed to immunise to prevent one RSV-related LRTI hospitalisation of 35.

INTERPRETATION: Chile's nirsevimab immunisation strategy significantly reduced RSV-related LRTI hospitalisations and more severe cases requiring intensive care. Our findings indicate a broader public health impact, with reductions also observed in all-cause LRTI hospitalisations. These results might encourage other countries to advance RSV prevention efforts.

FUNDING: Instituto Sistemas Complejos de Ingeniería and the Ministry of Health of Chile.

TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.

**中文摘要译文：**
背景：用于预防呼吸道合胞病毒（RSV）的尼塞韦单抗于2023年在北半球部分国家引入。智利是南半球首个实施全民策略的国家。我们旨在评估2024年智利RSV季节期间尼塞韦单抗的有效性及影响。

方法：该策略于2024年4月1日开始实施，至2024年9月30日结束，目标人群为2024年4月1日至2024年9月30日期间出生的婴儿（季节性新生儿队列），以及2023年10月1日至2024年3月31日期间出生的婴儿（补种队列）。利用来自10家对所有因下呼吸道感染（LRTI）住院患者进行普遍RSV检测的医院的历史监测和出院数据，我们识别了与2019年、2022年和2023年RSV季节期间RSV入院最密切相关的一组ICD-10编码。这些编码被应用于整合了三个全国性政府登记系统的国家数据库，以识别接受或未接受尼塞韦单抗的婴儿中与RSV相关的LRTI住院情况（主要终点）。次要终点包括RSV相关重症监护病房（ICU）入院、全因LRTI住院以及出生后至少7天发生的全因住院。使用分层Cox比例风险模型估计尼塞韦单抗有效性，计算为（1-风险比）乘以100，并给出95%置信区间。我们还通过与未引入尼塞韦单抗的反事实情景进行比较，评估了尼塞韦单抗的影响，估计了避免的病例数、相对减少率以及避免一例病例需要免疫的人数。本研究已在ClinicalTrials.gov注册，编号NCT06511687（已完成）。

结果：从整合数据库中提取了157,709名具有完整记录的婴儿数据。在排除1247名数据缺失或损坏的婴儿以及2289名免疫状态无法确定的婴儿后，154,173名婴儿被纳入主要分析。婴儿的中位年龄为6.27个月（四分位距3.20-9.17）。76,045名（49.32%）婴儿为女性，78,128名（50.68%）为男性。策略实施结束时，有145,087名婴儿接受了免疫，其中72,246名（49.79%）属于补种队列，72,841名（50.21%）属于季节性队列。在控制了年龄、性别、地理区域和孕周后，尼塞韦单抗（针对补种和季节性队列合并）对RSV相关LRTI住院的有效性为76.41%（95% CI 72.57-79.72），对RSV相关ICU入院的有效性为84.94%（79.47-88.95），对全因LRTI住院的有效性为66.50%（61.97-70.50），对全因住院的有效性为47.90%（44.35-51.21）。我们估计RSV相关LRTI住院相对减少了77.46%，每1000名婴儿避免了30.05例病例，预防一例RSV相关LRTI住院需要免疫的人数为35。

解读：智利的尼塞韦单抗免疫策略显著减少了RSV相关的LRTI住院以及需要重症监护的更严重病例。我们的研究结果表明其具有更广泛的公共卫生影响，全因LRTI住院也有所减少。这些结果可能鼓励其他国家推进RSV预防工作。

资助：智利复杂工程系统研究所和智利卫生部。

翻译：摘要的西班牙语翻译请参见补充材料部分。

### 第二部分 AI 大师评价

本研究是南半球首个评估尼塞韦单抗在全民免疫策略中实际效果的回顾性观察研究，具有重要的开创性意义。研究采用大规模国家数据库（154,173名婴儿）和严谨的分层Cox模型，证实尼塞韦单抗对RSV相关LRTI住院保护效果达76.41%，对ICU入院保护效果更高达84.94%，显示出卓越的临床价值。研究创新性地评估了该策略的公共卫生影响，发现还能显著减少全因LRTI住院和全因住院，为全球RSV预防策略提供了强有力的循证依据。虽然作为观察性研究存在一定局限性，但其大规模真实世界数据为其他国家制定RSV免疫政策提供了重要参考。

---

## 19. 成人因利妥昔单抗治疗后疫苗接种后体液免疫丧失而继发麻疹相关噬血细胞性淋巴组织细胞增生症（HLH）

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40480240](https://pubmed.ncbi.nlm.nih.gov/40480240)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40480240
**DOI：** 10.1016/S1473-3099(25)00223-3

### 第一部分 原文与翻译

**英文原标题：** Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab.

**英文摘要原文：**
Measles is an important re-emergent infectious disease globally. Vaccine immunity at the population level is key to the prevention of outbreaks, as unvaccinated or immunosuppressed adults are particularly vulnerable to severe infection. With the increasing use of immunomodulatory treatments for autoimmune and malignant conditions, the long-term effects of CD20-expressing cell-depleting therapies on the vaccine-induced humoral immunity to measles remain unclear. Haemophagocytic lymphohistiocytosis (HLH) is a hyperinflammatory syndrome with high mortality commonly triggered by infection and is possibly under-reported in association with measles. In this Grand Round, we describe the first reported case of secondary HLH following measles in an adult patient. The patient had proven adequate immunological response to measles vaccination but subsequently, 6 years before this presentation, the patient had received treatment with rituximab (an anti-CD20 monoclonal antibody) for relapsed autoimmune haemolytic anaemia. This case shows the need for further study of humoral immunity to diseases such as measles when using anti-CD20 therapies, such as rituximab. Furthermore, this case highlights the need for multidisciplinary input in the early recognition and prompt management of HLH, which is a potentially fatal complication of measles infection.

**中文摘要译文：**
麻疹是全球范围内重要的再发传染病。人群水平的疫苗免疫是预防疫情暴发的关键，因为未接种疫苗或免疫抑制的成人特别容易发生严重感染。随着免疫调节治疗在自身免疫性疾病和恶性肿瘤中的应用日益增多，表达CD20的细胞清除疗法对麻疹疫苗接种诱导的体液免疫的长期影响仍不清楚。噬血细胞性淋巴组织细胞增生症（HLH）是一种高炎症综合征，死亡率高，通常由感染引发，且与麻疹相关的报道可能不足。在本期大查房中，我们描述了首例成人麻疹后继发HLH的报道病例。该患者已证实对麻疹疫苗接种有充分的免疫应答，但随后在本病例发生前6年，患者因复发性自身免疫性溶血性贫血接受了利妥昔单抗（一种抗CD20单克隆抗体）治疗。该病例表明，在使用抗CD20疗法（如利妥昔单抗）时，需要进一步研究对麻疹等疾病的体液免疫。此外，该病例强调了多学科协作在早期识别和及时处理HLH中的必要性，HLH是麻疹感染的一种潜在致命并发症。

### 第二部分 AI 大师评价

本研究通过首例成人麻疹后继发HLH的病例报道，揭示了利妥昔单抗治疗对疫苗接种后麻疹体液免疫的长期影响。研究采用临床病例报告方法，详细描述了患者在证实有充分疫苗接种免疫应答后，因利妥昔单抗治疗导致免疫丧失而发展为严重HLH的过程。该研究的创新性在于首次报道了抗CD20治疗与麻疹后HLH的关联，填补了免疫调节治疗对疫苗保护效果影响的认识空白。临床价值重大，提醒临床医生关注免疫抑制患者接种疫苗后的长期免疫保护问题，并为HLH的早期识别和多学科管理提供了重要参考。局限性在于为单病例报告，需要更大样本研究验证这一发现。

---

## 20. 新发与再现传染病（RAPID）污名化量表：一项跨疫情量表开发与心理测量学验证研究

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40456231](https://pubmed.ncbi.nlm.nih.gov/40456231)
**期刊：** The Lancet. Infectious diseases
**PMID：** 40456231
**DOI：** 10.1016/S1473-3099(25)00161-6

### 第一部分 原文与翻译

**英文原标题：** The (Re)-emerging And ePidemic Infectious Diseases (RAPID) Stigma Scales: a cross-outbreak scale development and pyschometric validation study.

**英文摘要原文：**
Reducing stigma during infectious disease outbreaks is crucial for delivering an effective response. However, no validated stigma scales exist for use across outbreaks, and outbreak-specific scales are developed too slowly to guide timely interventions. To enable more real-time monitoring and mitigation of stigma across outbreak contexts, we developed and validated the (Re)-emerging and ePidemic Infectious Diseases (RAPID) Stigma Scales. Field testing and psychometric validation were conducted in communities affected by Ebola disease in Uganda, mpox in the UK, and Nipah virus disease in Bangladesh. Content validity was established through cognitive interviews and expert Delphi scoring. 1008 respondents were included across the three countries. The final RAPID Community Stigma Scale (12 items) captures initial social stigma, provider or authority-related stigma, structural stigma, and enduring social stigma. The RAPID Self Stigma Scale (4 items) is unidimensional. Both scales were found to have robust psychometric properties, including content validity, structural validity (factor loadings ≥0·6), and reliability (ordinal alphas 0·79-0·92). High scores on both scales predicted an increased hesitancy to report symptoms and seek care. The RAPID Stigma Scales are validated tools for real-time assessment of stigma across outbreak settings, enabling responders to design targeted interventions to improve health outcomes and promote equitable care.

**中文摘要译文：**
在传染病暴发期间减少污名化对于提供有效应对至关重要。然而，目前尚无经过验证的跨疫情污名化量表，而针对特定疫情开发的量表进展过于缓慢，无法指导及时干预。为了实现跨疫情背景下污名化的实时监测和缓解，我们开发并验证了新发与再现传染病（RAPID）污名化量表。实地测试和心理测量学验证在乌干达埃博拉病、英国猴痘和孟加拉国尼帕病毒病影响的社区中进行。通过认知访谈和专家德尔菲评分建立了内容效度。三个国家共纳入1008名受访者。最终的RAPID社区污名化量表（12个条目）捕捉了初始社会污名、服务提供者或权威相关污名、结构性污名和持久性社会污名。RAPID自我污名化量表（4个条目）为单维度量表。两个量表均显示出稳健的心理测量学特性，包括内容效度、结构效度（因子载荷≥0.6）和信度（序数α系数0.79-0.92）。两个量表的高分预测了报告症状和寻求护理的犹豫程度增加。RAPID污名化量表是经过验证的工具，可用于跨疫情环境中污名化的实时评估，使应对者能够设计有针对性的干预措施，以改善健康结局并促进公平护理。

### 第二部分 AI 大师评价

本研究开发并验证了首个跨疫情通用的污名化评估工具——RAPID污名化量表，填补了传染病暴发期间污名化实时监测的空白。研究采用多国实地验证策略，在乌干达、英国和孟加拉国三个不同疫情背景下进行心理测量学评估，确保了量表的跨文化适用性。关键创新在于开发了包含12个条目的社区污名化量表和4个条目的自我污名化量表，分别捕捉多维度和单维度的污名化特征。研究证实量表具有优良的心理测量学特性，且高分与症状报告和就医犹豫显著相关，为公共卫生应对提供了及时有效的评估工具。该研究的局限性在于样本主要来自三个特定疫情背景，未来需要在更广泛的疫情环境中进一步验证其普适性。

---

速递结束，祝您工作愉快！